• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapy and medication do not work for many people suffering from depression. A customized treatment could be the answer.

Cue is an intervention platform that converts sensors that are passively gathered from smartphones into personalized micro-interventions to improve mental health. We analysed the best-fit personalized ML models for each subject using Shapley values to understand their predictors of feature and reveal distinct characteristics that can be used to predict changes in mood with time.

Predictors of Mood

Depression is a leading cause of mental illness across the world.1 Yet, only half of those with the condition receive treatment. To improve outcomes, healthcare professionals must be able to recognize and treat patients who are most likely to respond to certain treatments.

The treatment of depression can be personalized to help. Using mobile phone sensors, an artificial intelligence voice assistant, and other digital tools, researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from which treatments. With two grants awarded totaling over $10 million, they will use these tools to identify biological and behavioral predictors of the response to antidepressant medication and psychotherapy.

To date, the majority of research on predictors for depression treatment effectiveness has been focused on sociodemographic and clinical characteristics. These include demographic variables like age, sex and educational level, clinical characteristics like symptom severity and comorbidities, and biological markers like neuroimaging and genetic variation.

Few studies have used longitudinal data to determine mood among individuals. They have not taken into account the fact that moods vary significantly between individuals. Therefore, it is essential to develop methods that allow for the identification of different mood predictors for each person and treatments effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to develop algorithms that can systematically identify various patterns of behavior and emotion that vary between individuals.

The team also devised a machine learning algorithm to model dynamic predictors for each person's mood for depression. The algorithm combines these individual differences into a unique "digital phenotype" for each participant.

This digital phenotype has been linked to CAT DI scores that are a psychometrically validated symptoms severity scale. The correlation was low, however (Pearson r = 0,08; BH adjusted P-value 3.55 x 10 03) and varied greatly between individuals.

Predictors of symptoms

Depression is among the world's leading causes of disability1 but is often not properly diagnosed and treated. Depression disorders are usually not treated due to the stigma associated with them, as well as the lack of effective treatments.

To facilitate personalized treatment, identifying predictors of symptoms is important. The current methods for predicting symptoms rely heavily on clinical interviews, which aren't reliable and only reveal a few symptoms associated with depression.

Machine learning can be used to blend continuous digital behavioral phenotypes of a person captured by smartphone sensors and an online mental health tracker (the Computerized Adaptive Testing depression treatment nice Inventory the CAT-DI) along with other indicators of severity of symptoms could improve diagnostic accuracy and increase the effectiveness of treatment for depression. Digital phenotypes can be used to are able to capture a variety of unique actions and behaviors that are difficult to document through interviews, and allow for high-resolution, continuous measurements.

The study involved University of California Los Angeles students with mild to severe depression symptoms who were participating in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA depression treatment nice Grand Challenge. Participants were directed to online support or to clinical treatment according to the severity of their depression treatment techniques. Those with a score on the CAT-DI scale of 35 65 were assigned to online support with the help of a peer coach. those who scored 75 patients were referred to clinics in-person for psychotherapy.

At the beginning of the interview, participants were asked the answers to a series of questions concerning their personal characteristics and psychosocial traits. The questions covered education, age, sex and gender, marital status, financial status, whether they were divorced or not, their current suicidal thoughts, intent or attempts, and the frequency with which they consumed alcohol. Participants also rated their degree of depression symptom severity on a scale of 0-100 using the CAT-DI. CAT-DI assessments were conducted every other week for the participants that received online support, and weekly for those receiving in-person treatment.

Predictors of the Reaction to Treatment

Personalized depression treatment is currently a research priority and a lot of studies are aimed at identifying predictors that will allow clinicians to identify the most effective medications for each patient. Pharmacogenetics, in particular, uncovers genetic variations that affect the way that our bodies process drugs. This lets doctors select the medication that will likely work best for every patient, minimizing the time and effort needed for trials and errors, while eliminating any adverse consequences.

Another promising method is to construct models of prediction using a variety of data sources, including the clinical information with neural imaging data. These models can be used to determine which variables are the most likely to predict a specific outcome, like whether a drug will improve mood or symptoms. These models can be used to predict the response of a patient to a treatment, allowing doctors to maximize the effectiveness.

A new era of research employs machine learning techniques such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of multiple variables and improve the accuracy of predictive. These models have been demonstrated to be effective in predicting outcomes of treatment for example, the response to antidepressants. These approaches are becoming more popular in psychiatry, and are likely to become the standard of future treatment.

In addition to prediction models based on ML research into the mechanisms behind postpartum depression treatment near me is continuing. Recent findings suggest that depression is linked to the dysfunctions of specific neural networks. This suggests that an individualized treatment for depression will be based on targeted therapies that restore normal functioning to these circuits.

Internet-based-based therapies can be a way to achieve this. They can provide more customized and personalized experience for patients. For example, one study found that a web-based program was more effective than standard care in alleviating symptoms and ensuring an improved quality of life for those with MDD. A controlled study that was randomized to an individualized treatment for depression found that a substantial percentage of participants experienced sustained improvement as well as fewer side consequences.

Predictors of adverse effects

A major issue in personalizing depression treatment is predicting which antidepressant medications will cause the least amount of side effects or none at all. Many patients are prescribed a variety medications before settling on a treatment that is safe and effective. Pharmacogenetics provides an exciting new method for an effective and precise approach to selecting antidepressant treatments.

A variety of predictors are available to determine the best antidepressant to prescribe, such as gene variations, phenotypes of patients (e.g. sexual orientation, gender or ethnicity) and co-morbidities. To identify the most reliable and accurate predictors for a specific treatment, randomized controlled trials with larger numbers of participants will be required. This is due to the fact that the identification of interaction effects or moderators may be much more difficult in trials that only take into account a single episode of treatment per person, rather than multiple episodes of treatment over a period of time.

Furthermore, the prediction of a patient's response to a specific medication will likely also require information on symptoms and comorbidities and the patient's prior subjective experience of its tolerability and effectiveness. Currently, only a few easily identifiable sociodemographic variables and clinical variables seem to be consistently associated with response to MDD. These include age, gender and race/ethnicity as well as BMI, SES and the presence of alexithymia.

Many challenges remain in the use of pharmacogenetics to treat depression. First, a clear understanding of the underlying genetic mechanisms is required as well as a clear definition of what is a reliable indicator of treatment response. In addition, ethical issues such as privacy and the responsible use of personal genetic information, should be considered with care. In the long term, pharmacogenetics may offer a chance to lessen the stigma associated with mental health treatment resistant bipolar depression and to improve the outcomes of those suffering with depression. Like any other psychiatric treatment it is crucial to carefully consider and implement the plan. For now, it is recommended to provide patients with an array of depression medications that are effective and encourage patients to openly talk with their doctor.